Literature DB >> 32334088

SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?

Giuseppe Magro1.   

Abstract

Entities:  

Keywords:  Baricitinib; COVID-19; Corona virus cycle; Coronavirus; Coronaviruses; Drugs; Hydroxychloroquine; Remdesivir; SARS-CoV; SARS-CoV-2; Strategies; Targets; Therapies; Tocilizumab

Mesh:

Substances:

Year:  2020        PMID: 32334088      PMCID: PMC7175862          DOI: 10.1016/j.tmaid.2020.101685

Source DB:  PubMed          Journal:  Travel Med Infect Dis        ISSN: 1477-8939            Impact factor:   6.211


× No keyword cloud information.
  3 in total

1.  A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19.

Authors:  Zohreh Esam
Journal:  Diabetes Res Clin Pract       Date:  2020-06-25       Impact factor: 5.602

2.  Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.

Authors:  Victoria Birlutiu; Rares Mircea Birlutiu; Liana Chicea
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

Review 3.  Recent advances in antibody-based immunotherapy strategies for COVID-19.

Authors:  Abdolreza Esmaeilzadeh; Samaneh Rostami; Pegah M Yeganeh; Safa Tahmasebi; Majid Ahmadi
Journal:  J Cell Biochem       Date:  2021-06-23       Impact factor: 4.480

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.